CompletedPhase 3

Tanezumab in Osteoarthritis of the Hip or Knee (2)

United States849 participantsStarted 2009-06-09

Plain-language summary

Test the efficacy and safety of 2 doses of tanezumab compared with naproxen and placebo in patients with osteoarthritis

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Osteoarthritis of the hip or knee according to Kellgren-Lawrence x-ray grade of 2 Exclusion Criteria: * pregnancy or intent to become pregnant * BMI greater than 39 * other severe pain, significant cardiac, neurological or psychiatric disease

What they're measuring

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

Timeframe: Baseline, Week 16

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

Timeframe: Baseline, Week 16

Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)

Timeframe: Baseline, Week 16

Trial details

NCT IDNCT00863304

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-04-27

Results submitted2021-04-20

View on ClinicalTrials.gov More Osteoarthritis trials